A new treatment for squamous cell lung cancer using targeted therapy
R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma
This study is testing a new treatment for squamous cell lung cancer that uses a special drug designed to deliver chemotherapy directly to cancer cells, which could help patients feel better and live longer while protecting healthy tissues.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10671669 on NIH RePORTER |
What this research studies
This research investigates a novel therapy for squamous cell lung carcinoma (SCC) that utilizes an antibody-drug conjugate (ADC) to deliver a potent chemotherapy drug directly to cancer cells. The approach targets tumors that overexpress a specific receptor, allowing for more effective treatment while minimizing damage to healthy tissues. By using a new method for drug conjugation, the therapy aims to enhance the stability and efficacy of the treatment. Patients with SCC may benefit from this targeted approach, which could lead to improved survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with squamous cell lung carcinoma who have limited treatment options.
Not a fit: Patients with other types of lung cancer or those who do not have squamous cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with squamous cell lung carcinoma, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise with similar antibody-drug conjugate approaches in treating various cancers, suggesting potential for success in this novel application.
Where this research is happening
Boston, United States
- Boston University (Charles River Campus) — Boston, United States (Active)
Researchers
- Principal investigator: Grinstaff, Mark W. — Boston University (Charles River Campus)
- Study coordinator: Grinstaff, Mark W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.